Result of General Meeting

Dec 19, 2011

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

RNS Number : 2390U
Advanced Medical Solutions Grp PLC
19 December 2011

19 December 2011


Advanced Medical Solutions Group plc

(“AMS” or the “Company”)


Result of General Meeting


The Board of AMS (AIM: AMS), the global medical technology company, is pleased to announce that the Resolutions proposed at the General Meeting held today at 11.00 a.m. at the offices of Investec Bank plc, 2 Gresham Street, London EC2V 7QP, in connection with the proposed Placing to raise approximately £34.0 million for the proposed acquisition of RESORBA® announced on 2 December 2011, were duly passed without amendment.


The Placing remains conditional upon the Placing Agreement becoming unconditional in all respects and upon Admission.


Application has been made to AIM for the Admission of 48,214,415 ordinary shares of 5 pence each in connection with the Placing and Acquisition. It is expected that Admission will become effective on 20 December 2011 and that dealings in the New Ordinary Shares will commence at 8.00 a.m. on 20 December 2011.


The New Ordinary Shares (in uncertificated form) are expected to be credited to CREST accounts on or around 8.00 a.m. on 20 December 2011 and definitive share certificates for the New Ordinary Shares (in certificated form) are expected to be despatched to certificated shareholders by no later than 4 January 2012.


The New Ordinary Shares will be issued credited as fully paid and will, on issue, rank equally in all respects with the Existing Ordinary Shares, including the right to receive all dividends or other distributions made, paid or declared after Admission.


On Admission, the Company’s issued share capital will consist of 203,516,367 Ordinary Shares.


For further information, please contact:

Advanced Medical Solutions Group plc                    

Chris Meredith, Chief Executive Officer

Mary Tavener, Finance Director


Tel: +44 (0) 1606 545508

Investec Bank plc (NOMAD) and Broker

Gary Clarence

Patrick Robb

Daniel Adams

Cara Griffiths


Tel: +44 (0) 20 7597 5970

Tavistock Communications

John West

Chris Munden

Andrew Dunn


Tel: +44 (0) 20 7920 3150


Investec Bank plc, which is authorised and regulated in the United Kingdom by the FSA, is acting as nominated adviser, broker and underwriter to AMS in relation to the Placing and Admission and is not acting for any other persons in relation to the Placing and Admission. Investec Bank plc is acting exclusively for AMS and for no one else in relation to the matters described in this announcement and is not advising any other person and accordingly will not be responsible to anyone other than AMS for providing the protections afforded to clients of Investec Bank plc, or for providing advice in relation to the contents of this announcement or any matter referred to in it. The responsibilities of Investec Bank plc as AMS’s nominated adviser and broker under the AIM Rules for Companies and the AIM Rules for Nominated Advisers are owed solely to the London Stock Exchange and are not owed to AMS or to any Director, Shareholder or any other person, in respect of any decision to acquire or dispose of shares in the capital of AMS in reliance on any part of this announcement, or otherwise.


No liability is accepted by Investec Bank plc nor does it make any representation or warranty, express or implied, in relation to, the contents of this announcement, including its accuracy, completeness or verification or for any other statement made or purported to be made by it, or on its behalf, in connection with the Company and the Placing and accordingly Investec Bank plc disclaims all and any responsibility or liability whether arising in tort, contract or otherwise which it might otherwise have in respect of this announcement or any such statement. Investec Bank plc has not authorised the contents, or any part, of this announcement. Investec Bank plc may, in accordance with applicable legal and regulatory provisions, engage in transactions in relation to the Ordinary Shares (including the Placing Shares) and/or related instruments for its own account for the purposes of hedging its underwriting exposure or otherwise. Except as required by applicable law or regulation, Investec Bank plc does not propose to make any public disclosure in relation to any such transactions.

This information is provided by RNS
The company news service from the London Stock Exchange




For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.